Armata Pharmaceuticals has achieved full enrollment in its Tailwind Phase 2 clinical study of inhaled AP-PA02 in patients with non-cystic fibrosis bronchiectasis, or NCFB, and chronic pulmonary Pseudomonas aeruginosa infection. The last patient final follow-up visit is scheduled for August 7. Armata anticipates topline data from the Tailwind study in the second half of 2024. Armata plans to meet with the FDA shortly after completion on the design of a pivotal Phase 3 study, planned to initiate in 2025. The primary endpoint is P. aeruginosa recovery in sputum following multiple doses of AP-PA02 administered by inhalation.